QuidelOrtho (NASDAQ:QDEL) Posts Quarterly Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Price Performance

Shares of NASDAQ:QDEL traded down $1.08 during trading hours on Friday, hitting $40.57. 1,445,774 shares of the company's stock traded hands, compared to its average volume of 828,934. QuidelOrtho has a 52 week low of $29.74 and a 52 week high of $49.56. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.81 and a current ratio of 1.38. The company's fifty day simple moving average is $43.41 and its two-hundred day simple moving average is $42.39. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -1.45 and a beta of 0.08.

Analyst Upgrades and Downgrades

Several research firms have commented on QDEL. StockNews.com cut shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday. UBS Group raised their target price on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a research note on Thursday. Royal Bank of Canada lowered their target price on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research note on Thursday. Jefferies Financial Group began coverage on shares of QuidelOrtho in a research note on Tuesday, December 10th. They set a "hold" rating and a $43.00 target price on the stock. Finally, William Blair reissued a "market perform" rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $51.20.

Insider Activity

In other news, CEO Brian J. Blaser bought 6,033 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was bought at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the acquisition, the chief executive officer now directly owns 6,033 shares in the company, valued at $249,886.86. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the firm's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The disclosure for this sale can be found here. Insiders own 1.00% of the company's stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.